Drug – bio-affecting and body treating compositions – Designated organic nonactive ingredient containing other... – Carboxylic acid or salt thereof
Reexamination Certificate
2005-05-03
2005-05-03
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic nonactive ingredient containing other...
Carboxylic acid or salt thereof
C514S946000, C514S04400A, C536S023100, C536S024500
Reexamination Certificate
active
06887906
ABSTRACT:
The present invention relates to compositions and methods which enhance the transport of nucleic acids, especially oligonucleotides at various sites in the alimentary canal of an animal. The methods and compositions enhance the transport of oligonucleotides across the mucosa of the alimentary canal via the use of one or more penetration enhancers. The invention features the use of various fatty acids, bile salts, chelating agents and other penetration enhancers, as well as carrier compounds, to enhance the stability of nucleic acids and/or their transport across and/or into cells of the alimentary canal. In one preferred embodiment, the compositions and methods of the invention are utilized to effect the oral delivery of an antisense oligonucleotide to an animal in order to modulate the expression of a gene in the animal for investigative, therapeutic or prophylactic purposes.
REFERENCES:
patent: 4689320 (1987-08-01), Kaji
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 4835263 (1989-05-01), Nguyen et al.
patent: 5004810 (1991-04-01), Draper
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5087617 (1992-02-01), Smith
patent: 5098890 (1992-03-01), Gewirtz et al.
patent: 5135917 (1992-08-01), Burch
patent: 5138045 (1992-08-01), Cook et al.
patent: 5166195 (1992-11-01), Ecker
patent: 5194428 (1993-03-01), Agrawal et al.
patent: 5212295 (1993-05-01), Cook
patent: 5218105 (1993-06-01), Cook et al.
patent: 5242906 (1993-09-01), Pagano et al.
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5286717 (1994-02-01), Cohen et al.
patent: 5298614 (1994-03-01), Yano et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5386023 (1995-01-01), Sanghvi et al.
patent: 5455335 (1995-10-01), Kahne et al.
patent: 5457191 (1995-10-01), Cook et al.
patent: 5459255 (1995-10-01), Cook et al.
patent: 5506351 (1996-04-01), McGee
patent: 5521302 (1996-05-01), Cook
patent: 5539082 (1996-07-01), Nielsen et al.
patent: 5539083 (1996-07-01), Cook et al.
patent: 5541307 (1996-07-01), Cook et al.
patent: 5543508 (1996-08-01), Haseloff et al.
patent: 5545729 (1996-08-01), Goodchild et al.
patent: 5554746 (1996-09-01), Ravikumar et al.
patent: 5571902 (1996-11-01), Ravikumar et al.
patent: 5578718 (1996-11-01), Cook et al.
patent: 5587361 (1996-12-01), Cook et al.
patent: 5587469 (1996-12-01), Cook et al.
patent: 5587470 (1996-12-01), Cook et al.
patent: 5591721 (1997-01-01), Agrawal et al.
patent: 5595978 (1997-01-01), Draper et al.
patent: 5599797 (1997-02-01), Cook et al.
patent: 5602240 (1997-02-01), De Mesmaeker et al.
patent: 5608046 (1997-03-01), Cook et al.
patent: 5610289 (1997-03-01), Cook et al.
patent: 5707648 (1998-01-01), Yiv
patent: 5780444 (1998-07-01), Kahne
patent: 5843738 (1998-12-01), Bennett et al.
patent: 5948898 (1999-09-01), Dean et al.
patent: 5955059 (1999-09-01), Gilchrest et al.
patent: 5994062 (1999-11-01), Mulshine et al.
patent: 6096722 (2000-08-01), Bennett et al.
patent: 57080314 (1982-05-01), None
patent: WO 9220813 (1992-11-01), None
patent: WO9221353 (1992-12-01), None
patent: WO 9319660 (1993-10-01), None
patent: WO 9324510 (1993-12-01), None
patent: WO 9400155 (1994-01-01), None
patent: WO9418835 (1994-09-01), None
patent: WO 9511748 (1995-05-01), None
patent: WO 9612497 (1996-05-01), None
patent: WO 9630051 (1996-10-01), None
patent: WO 9632496 (1996-10-01), None
patent: WO 9634008 (1996-10-01), None
patent: WO 9641011 (1996-12-01), None
patent: WO 9705903 (1997-02-01), None
patent: WO9705903 (1997-02-01), None
patent: WO 9712995 (1997-04-01), None
patent: WO9800110 (1998-01-01), None
patent: WO9833932 (1998-08-01), None
patent: WO 9849348 (1998-11-01), None
patent: WO9901579 (1999-01-01), None
Orkin et al. Report and recommendations of the panel to assess the NIH investment in research on gene therapy. 1995, p. 1-20.*
Agrawal et al. Antisense therapeutics: Is it as simple as complementary base recognition? Molecular Medicine Today, vol. 6:72-81, Feb. 2000.*
Branch A good antisense molecule is hard to find. TIBS, vol. 23:45-50, Feb. 1998.*
Rojanasakul, Y. Antisense oligonucleotide therapeutics: Drug delivery and targeting. Advanced Drug Delivery Reviews. vol. 18:115-131, Jan. 1996.*
Nolen, H.W., et al., “Percutaneous penetration of methyl phosphonate antisense oligonucleotides,” Intl. J. Pharm. (1994) 107:169-177.
Miller, K., et al., “In vitro transdermal flux and tissue distribution of interleukin 1 beta antisense methyl phosphonate oligonucleotide from topical formulations,” Pharm. Res. (1993) 10: (Supp 1) S252.
Lieb, L.M., et al., “Follicular permeation of oligonucleotides,” Proc. Controlled Release Soc. (1995) 22:654-655.
Nolen, H. W., “Percutaneous penetration of methyl phosphonate antisense oligonucleotides,”International J Pharmaceutics, 1994, 107, 169-177.
Walker, S., et al., “Catioinic facial amphiphiles: A promising class of transfection agents,”Proc. Natl. Acad. Sci. USA, 1996, 93, 1585-1590.
Akamo, Y. et al., “Chemotherapy Targeting Regional Lymph Nodes by Gastric Submucosal Injection of Liposomal Adriamycin in Patients with Gastric Carinoma”,Japanese J. Cancer Res., 1994, 85, 652-658.
Albert, P.R. et al., “Antisense knockouts: molecular scalpels for the dissection of signal transduction”,Trends Pharmacol. Sci., 1994, 15, 250-254.
Anonymous, “ISIS Pharmaceuticals Demonstrates Efficacy In Chrohn's Disease with its Antisense Drug”,Genetic Engineer. News., 1997, pp. 1 and 34.
Aungst, B.J. et al., “Site Dependence of Absorption-Promoting Actions of Laureth-9, Na Salicylate, Na2EDTA, and Aprotinin on Rectal, Nasal, and Buccal Insulin Delivery”,Pharm. Res., 1988, 5, 305-308.
Ausubel et al. (eds.),Short Protocols in Molecular Biology, 2d Ed., John Wiley and Sons, New York, NY, Chapter 3, 3-11 to 3-38.
Bailly, C. et al., “PCR-based development of DNA substrates containing modified bases: An efficient system for investigating the role of the exocyclic groups in chemical and structural recognition by minor groove binding drugs and proteins”,Proc. Natl. Acad. Sci. USA., 1996, 93, 13623-13628.
Beck, S., “Nonradioactive Detection of DNA Using dioxetane Chemiluminescence”,Methods in Enzymology, 1992, 216, 143-153.
Benet et al., Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, and Elimination,Goodman&Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al. (eds.), McGraw-Hill, New York, NY, 1996, Chapter 1, 3-9.
Berge, S.M. et al., “Pharmaceutical Salts”,J. Pharm. Sci., 1977, 66, 1-19.
Block, L., “Medicated Applications”,Remington's Pharmaceutical Sciences, 18th Ed., Gennaro (ed.), Mack Publishing Co., Easton, PA, 1990, Ch. 87, 1596-1614.
Brunton, L.L., “Agents Affecting Gastrointestinal Water Flux and motility; Emesis and Antiemetics; Bile Acids and Pancreatic Enzymes”,Goodman&Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al. (eds.), McGraw-Hill, New York, 1996, Chapter 38, 934-935.
Buur, A. et al., “Penetration of 5-Fluorouracil and prodrugs across the intestine of the albino rabbit: Evidence for shift in absorption site from the upper to the lower region of the gastrointestinal tract by prodrugs”,J. Controlled Release, 1990, 14, 43-51.
Buzayan, J.M. et al., “Satellite tobacco ringspot virus RNA: A subset of the RNA sequence is sufficient for autolytic processing”,Proc. Natl. Acad. Sci. USA, 1986, 83, 8859-8862.
Chollet, A. et al., “DNA containing the base analogue 2-aminoadenine: preparation, us as hybridization probes and cleavage by restriction endonucleases”,Nucl. Acids Res., 1988, 16, 305-317.
Constantinides, P.P. et al., “Formulation and Intestinal Absorption Enhancement Evaluation of Water-in-Oil Microemulsions Incorporating Medium-Chain Glycerides”,Pharm. Res., 1994, 11, 1385-1390.
Crooke, S.T., “Progress in Antisense Therapeutics”,Hematologic Pathology, 1995, 9, 59-72.
Crooke
Hardee Greg
Teng Ching-Leou
ISIS Pharmaceuticals, Inc.
ISISPharmaceuticals, Inc.
O'Connor Cozen
LandOfFree
Compositions and methods for the delivery of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the delivery of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the delivery of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3424804